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Background: Grass pollen is a major cause of respiratory allergy worldwide and contain a number of allergens,
some of theme (Phl p 1, Phl p 2, Phl p 5, and Phl 6 from Phleum pratense, and their homologous in other grasses)
are known as major allergens. The administration of grass pollen extracts by immunotherapy generally induces an
initial rise in specific immunoglobulin E (sIgE) production followed by a progressive decline during the treatment.
Some studies reported that immunotherapy is able to induce a de novo sensitisation to allergen component
previously unrecognized.
Methods: We investigated in 30 children (19 males and 11 females, mean age 11.3 years), 19 treated with
sublingual immunotherapy (SLIT) by a 5-grass extract and 11 untreated, the sIgE and sIgG4 response to the
different allergen components.
Results: Significant increases (p< 0.001) were detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6, while sIgE levels
induced in response to Phl p 7 and Phl p 12 were low or absent at baseline and unchanged following SLIT
treatment; no new sensitisation was detected. As to IgG4, significant increases were found for Phl p2 and Phl p 5,
while the increase for Phl p 12 was not significant. In the control group, no significant increase in sIgE for any
single allergen component was found.
Conclusions: These findings confirm that the initial phase of SLIT with a grass pollen extract enhances the sIgE
synthesis and show that the sIgE response concerns the same allergen components which induce IgE reactivity
during natural exposure.Introduction
Grass pollen is a major cause of respiratory allergy
worldwide [1,2]. Grasses are botanically classified in the
family of Gramineae and in particular in the subfamily
of Pooideae, which includes the species most commonly
responsible of allergic sensitisation, such as Anthoxan-
tum odoratum, Dactylis glomerata, Festuca elatior, Hol-
cus lanatus, Lolium perenne, Phleum pratense, and Poa
pratensis. Another species causing respiratory allergy is
Cynodon dactylon, which belongs to the subfamily of
Panicoideae. These species have variable importance in
different geographical areas. In Europe, Dactylis glomer-
ata, Poa pratensis, Lolium perenne and Anthoxantum* Correspondence: fmarcucci@yahoo.it
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reproduction in any medium, provided the orodoratum are homogeneously distributed, while Phleum
pratense is the dominant grass in Northern regions and
in the United Kingdom, and Cynodon dactylon is present
only in Southern regions [1]. To date, more than 150
allergens from 52 grass species are known, classified in
13 groups according to similar physicochemical and im-
munologic properties [3,4]. Among these allergens, the
molecules from Phleum pratense Phl p 1, Phl p 2, Phl p
5, and Phl 6, and their homologous in other grasses, are
known as major allergens [4]. The administration of a
pollen allergen extract by specific immunotherapy with
conventional schedules generally induces an initial rise
in specific immunoglobulin E (sIgE) production followed
by a progressive decline during the treatment. This event
was first observed in 1971 [5] and confirmed in a num-
ber of studies using subcutaneous immunotherapy
(SCIT), being reasonable to presume that the early riseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genic mechanisms of immunotherapy (such as the gener-
ation of IgG-blocking antibodies and changes in T cell
subpopulations) are not yet developed; subsequently,
when these mechanisms are initiated, sIgE synthesis is
inhibited [6]. Recent studies on sublingual immunother-
apy (SLIT) with administration of adequate allergen
doses have shown a pattern of sIgE response analogous
to that observed for SCIT [7-9], and this agrees with the
fact that the two treatments share similar mechanisms of
action [6,10]. Only a few studies evaluated the sIgE re-
sponse to single allergen components during immuno-
therapy with grass pollen extract [11-14] and only one
investigated this issue in SLIT with a Phleum pratense
extract in adults [14]. We evaluated the sIgE and sIgG4
response to the different allergen components in children
treated with SLIT using a 5-grass pollen extract.Materials and methods
Patients
The study included 30 children (19 males and 11 female,
mean age 11.3 years) with grass pollen allergy, present-
ing as persistent allergic rhinitis for at least 2 consecu-
tive years and graded as moderate/severe according to
the Allergic Rhinitis and its Impact on Asthma (ARIA)
classification [15]. Of them, 19 underwent SLIT with a
5-grass pollen extract standardized in Index of Reactivity
(IR) (Staloral 300 IR, Stallergenes, Antony, France),
while 11 patients were not treated and served as con-
trols. SLIT was performed by the build-up schedule in
four days (30 – 60 – 120 – 240 IR) suggested by the
manufacturer starting in the month of February. A
maintenance dose of 240 IR was then administered 3
times a-week until the end of June. All side effects were
recorded in diary cards. The study was approved by the
Ethics Committee of the University of Perugia.In vitro methods
The IgE reactivity to the single grass pollen allergen com-
ponents (Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, and
Phl p 12) was determined using ImmunoCAPW (Phadia
AB, Uppsala, Sweden) tests; IgG4 reactivity to Phl p 2,
Phl p 5 and Phl p 12 was also measured. sIgE and sIgG4
measurement was performed before starting SLIT and at
the end of the pollen season.Statistical analysis
Wilcoxon signed rank test for paired data was used to
detect differences between baseline and after SLIT values
of specific IgE and IgG antibodies for recombinant epi-
topes of Phleum pratense. A p value lower than 0.05 was
stated as significant.Results
The SLIT treatment was well tolerated, only local reac-
tions in the mouth were observed in 9 of the 19 treated
patients (47%), no systemic reaction occurred. Figure 1
shows the basal values of sIgE in both groups and the
mean changes in sIgE to grass allergen components in
SLIT treated children and in controls. Basal values were
not significantly different between SLIT treated and con-
trol patients. Significant increases (p< 0.001) were
detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6, while
sIgE levels induced in response to Phl p 7 and Phl p 12
were low or absent at baseline and unchanged following
SLIT treatment. In the control group, no significant in-
crease in sIgE for any single allergen component was
found. A significant increase of sIgG4 was detected for
Phl p 2 (p = 0.009), and Phl p 5 (p = 0.025), while sIgG4
for Phl p 12 showed a not significant increase (Figure 2).
Most patients had a similar increase in sIgE and sIgG4
reactivity, only one patient showed a slight increase of
sIgG4 to Phl p 12 (from 0.14 to 0.21 mg/L) with no
change in sIgE levels. No new sIgE sensitizations were
found in SLIT group.
Discussion
Of the 13 allergen groups identified in grass pollen, four
– Phl p 4, 7, 11, and 12 – are not grass-specific, while
the other groups are grass-specific. Considering the clas-
sification of allergens as major or minor depending on
their recognition by IgE antibodies from more or less
than 50% of sensitised patients, respectively, Group 1
and Group 5 contain the major grass pollen allergens.
Group 1 allergens are acidic glycoproteins, with a m.w.
of 31–35 kDA, and have high homology (about 90% of
the amino acid sequence) [16], while Group 5 allergens
are proteins showing ribonuclease activity, occurring in
two non-glycosilated isoforms, with a m.w. of 27–33
kDa, which have a lesser homology due to a 25-30% di-
vergence in amino acid sequence [4]. Instead, Phl p 7, a
calcium-binding protein, and Phl p 12, a profilin, are ubi-
quitous molecules showing cross-reactivity in a number
of allergen sources that are not naturally found as spe-
cific grass pollen allergens [4]. Due to the complex aller-
gen repertoire of grass pollen, the pattern of sIgE
response of sensitised individual is largely variable, espe-
cially concerning the recognition of the different epitopes
expressed in the various allergens. The sensitisation is
obviously influenced by the kind of exposure and par-
ticularly by the distribution of the different grasses in the
geographical area where the patients live. For example,
Phleum pratense clearly prevails in Northern Europe,
while is less present in central and southern Italy, as
demonstrated by phenologic studies [17]. The contact of
the immunologic system with the allergens introduced
by means of specific immunotherapy is a different kind
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Figure 1 Basal values of sIgE in pre-SLIT and control group (A) and changes in sIgE towards Phleum epitopes, before and after pollen
season in patients treated by grass SLIT (B) and in untreated control patients (C).
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sponse to allergen components previously not recognized
by natural exposure. This was true in the study by Ball et
al, who found a de novo induction of sIgE against new
allergens in one of 8 patients treated with SCIT with a
grass pollen extract. This finding lead the authors to
suggest the de novo sensitisation as a factor able toexplain the unpredictability of specific immunotherapy
performed with allergen extracts [11]. Similar observa-
tions were reported by Moverare et al. in a larger group
of 34 patients allergic to birch pollen treated with SCIT,
29% of whom developed new sensitizations to rBet v 2
and/or rBet v 4, though the sIgE levels were low and the
clinical relevance was not known [18]. Indeed, other
(A)
(B)
Figure 2 sIgG4 sensitization in patients treated by grass SLIT (A) and in untreated control patients (B).
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jects from North-West Italy [12] and 19 subjects from
Germany [13] treated with SCIT did not find any new
sensitisation. The only available study on sIgE profiles to
grass pollen allergens during SLIT was performed on 40
adults treated with a Phleum pratense extract in tablets.
Most patients had low titers of sIgE to Phl p 1 and Phl p
5 before SLIT and showed a dose-dependent increase
during the treatment, while sIgE titers to Phl p 7 and Phl
p 12 were very low both before and after SLIT; no new
sensitisation was detected [14].
We addressed the present study to evaluate the
changes in sIgE levels to Phl p 1, Phl p 2, Phl p 5, Phl p
6, Phl p 7, and Phl p 12 in children treated with SLITusing a 5-grass extract which was demonstrated to be
immunologically effective [19,20]. Significant increases
were detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6,
but not for Phl p 7 and Phl p 12, which maintained the
pre-treatment low levels. We confirmed the lack of new
sensitisations, and this is important because the im-
munologic stimulation given by a 5-grass extract is wider
than that by an extract with a single grass. Also sIgG4
were measured, with detection of significant increase for
Phl p 2 and Phl p 5 but not for Phl p 12. Concerning the
latter, the mild increase (from 0.14 to 0.21 mg/ml)
excludes that the low level of sIgE was influenced by the
blocking activity of IgG4. For the other allergens, a sub-
stantially parallel pattern of IgE and IgG4 response was
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vations [14]. Our results cannot be generalized, consid-
ering the extreme heterogeneity of the immune-response
to grass pollen, as recently reported by Tripodi et al.
[21]. In particular, it is not known whether the produc-
tion of sIgE to the different allergen components is
influenced by only genetic predisposition or also by the
kind of allergen exposure. In addition, it remains to be
investigated if a prolonged period of observation during
SLIT could detect changes in sIgE specificities not oc-
curring in early phases of treatment.
Conclusions
The findings of this study confirm that the initial phase
of SLIT with a grass pollen extract enhances the sIgE
synthesis and show that the sIgE response concerns the
same allergen components which induce IgE reactivity
during natural exposure. The observation seems import-
ant where IgE response to individual pollen components
is concerned and warrants further research to confirm
and expand the knowledge on this issue.
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